NewsBenzingaMaxCyte To Acquire Akron BioProducts From Arcline Investment Management For Total Consideration Of $151.8M, Comprising $105M In Cash And 20.6M MXCT Shares Worth ~$26.8M MaxCyte To Acquire Akron BioProducts From Arcline Investment Management For Total Consideration Of $151.8M, Comprising $105M In Cash And 20.6M MXCT Shares Worth ~$26.8M Benzinga 2026.11.10 11:07 (GMT+0) Open on Benzinga Other news Motorola Solutions Hikes Quarterly Dividend From $1.21 To $1.34 Per Share These 9 Congress Members Could Have Increased Interest in Nvidia’s Q3 Earnings as 2026 Shareholders $100 Invested In Cigna Group 20 Years Ago Would Be Worth This Much Today Needham Maintains Buy on FuboTV, Lowers Price Target to $10 BTIG Reiterates Buy on Amer Sports, Maintains $42 Price Target Ahead of Palo Alto Networks Earnings, Here's What Barchart Data Says Comes Next for PANW Stock